75415-01-9

Basic information

• Product Name: 3-(diMethylaMino)-1-(pyridin-3-yl)prop-2-en-1-one
• Synonyms: (Z)-3-(dimethylamino)-1-pyridin-3-ylprop-2-en-1-one
• CAS NO: 75415-01-9
• Molecular Formula: C₁₀H₁₂N₂O
• Molecular Weight: 176.21508
• Mol File: 75415-01-9.mol
• Article Data: 85

Chemical Properties

• Boiling Point: 281.4±36.0 °C(Predicted)
• Appearance: /
• Density: 1.070±0.06 g/cm3(Predicted)
• PKA: 4.74±0.70(Predicted)
• CAS DataBase Reference: 3-(diMethylaMino)-1-(pyridin-3-yl)prop-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(diMethylaMino)-1-(pyridin-3-yl)prop-2-en-1-one(75415-01-9)
• EPA Substance Registry System: 3-(diMethylaMino)-1-(pyridin-3-yl)prop-2-en-1-one(75415-01-9)

Safety Data

• Hazardous Substances Data: 75415-01-9(Hazardous Substances Data)

Upstream product

• 350-03-8 methyl-3-pyridylketone 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 109-94-4 formic acid ethyl ester 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 
• 68-12-2 N,N-dimethyl-formamide 
• 124-40-3 dimethyl amine 
• 5762-56-1 tris(dimethylamino)methane 
• 6006-65-1 N,N-dimethylformamide dipropyl acetal 
• 5815-08-7 tert-Butoxybis(dimethylamino)methane 

Downstream Products

• 112722-57-3 4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid, ethyl ester 
• 112676-46-7 N-(2-methoxyphenyl)-4-(3-pyridinyl)-2-pyrimidinamine 
• 112675-67-9 N-(4-methoxyphenyl)-4-(pyridin-3-yl)pyrimidin-2-amine 
• 78561-98-5 7-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile 
• 78562-03-5 ethyl 7-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate 
• 917392-54-2 methyl 4-methyl-3 -[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzoate 
• 152460-09-8 N-(5-nitro-2-methylphenyl)-4-(3-pyridinyl)-2-pyrimidineamine 
• 641569-94-0 4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzoic acid 
• 1206604-20-7 N-5-bromo-2-methylphenyl(4-pyridine-3-yl)pyrimidine-2-amine 
• 796738-67-5 N,N-(4-methyl-3-nitrophenyl)[4-(pyridin-3-yl)-pyrimidin-2-yl]amine 
• 796738-71-1 N-(2-methyl-4-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine 
• 108-78-1 2,4,6-triamino-s-triazine 
• 1144477-16-6 N-[4-(pyridin-3-yl)pyrimidin-2-yl]cyanamide 
• 127099-85-8 N-Cyanoguanidine 

Relevant articles and documents

Method for preparing N-(5-carboxyl-2-methylphenyl)-4-(3-pyridine)-2-pyrilamine

The invention discloses a method for preparing N-(5-carboxyl-2-methylphenyl)-4-(3-pyridine)-2-pyrilamine. The method specifically comprises the following steps: step 1, carrying out ethyl esterification reaction on 3-nitro-4-methyl benzoic acid serving as an initial raw material to generate a compound 2; step 2, reducing nitro of the compound 2 through hydrogenation reduction reaction in the presence of palladium on carbon to generate a compound 3; step 3, reacting the compound 3 with a nitrile amine aqueous solution, and then carrying out base exchange to obtain a compound 4; step 4, carrying out cyclization between the compound 4 and a compound 6 to obtain a compound 7; and step 5, hydrolyzing the compound 7 under the action of an alkaline to generate a compound 8, namely N-(5-carboxyl-2-methylphenyl)-4-(3-pyridine)-2-pyrilamine. The method overcomes the defects that in the prior art such as long reaction time, low yield, high cost, difficulty for industrial production, and the like. A preparation method, which is high in yield, is environmentally-friendly, and is suitable for industrial production, is provided.

Microscale Parallel Synthesis of Acylated Aminotriazoles Enabling the Development of Factor XIIa and Thrombin Inhibitors

Herein we report a microscale parallel synthetic approach allowing for rapid access to libraries of N-acylated aminotriazoles and screening of their inhibitory activity against factor XIIa (FXIIa) and thrombin, which are targets for antithrombotic drugs. This approach, in combination with post-screening structure optimization, yielded a potent 7 nM inhibitor of FXIIa and a 25 nM thrombin inhibitor; both compounds showed no inhibition of the other tested serine proteases. Selected N-acylated aminotriazoles exhibited anticoagulant properties in vitro influencing the intrinsic blood coagulation pathway, but not extrinsic coagulation. Mechanistic studies of FXIIa inhibition suggested that synthesized N-acylated aminotriazoles are covalent inhibitors of FXIIa. These synthesized compounds may serve as a promising starting point for the development of novel antithrombotic drugs.

Synthesis method of imatinib and imatinib mesylate

The invention relates to a synthesis method of imatinib and imatinib mesylate. The method comprises the following steps: condensing 3-acetylpyridine and N,N-dimethylformamide dimethyl acetal which aretaken as initial raw materials to obtain 3-dimethylamino-1-(3-pyridyl)-2-propen-1-one, then reacting with 2-methyl-5-nitrophenylguanidine nitrate to form a pyrimidine ring, performing nitro reductionto obtain N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine, amidating the N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine and 4-(chloromethyl)benzoyl chloride, performing affinitysubstitution with 1-methylpiperazine to obtain imatinib, and salifying the imatinib and methanesulfonic acid. The products obtained by the method have the advantages of few impurities, simplicity in post-treatment, high total yield, greenness, environmental protection and safety, and is suitable for a production process for large-scale industrial production of imatinib mesylate.